Anti-HLA-DR antibody [10-D8]

Anti-HLA-DR antibody [10-D8]

• 概述

• 产品描述Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in mhc ii-a/b dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.
• 产品名称Anti-HLA-DR antibody [10-D8]
• 分子量29 kDa
• 种属反应性Human
• 验证应用WB,IHC-P,FC
• 抗体类型小鼠单抗
• 免疫原Peptide
• 偶联Non-conjugated

• 性能

• 形态Liquid
• 浓度2 mg/mL.
• 存放说明Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles.
• 存储缓冲液1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.
• 亚型IgG1
• 纯化方式Peptide affinity purified
• 亚细胞定位Cell membrane. Endoplasmic reticulum membrane. 
• 其它名称
  • DR alpha chain antibody
  • DR alpha chain precursor antibody
  • DRA_HUMAN antibody
  more

• 应用

  WB: 1:500-1:1,000
  IHC-P: 1:50-1:200
  FC: 1:50-1:200

•  

  

  Fig1: Western blot analysis of HLA-DR on Raji cell lysate using anti-HLA-DR antibody at 1/1,000 dilution.

   

  

  Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.

   

  

  Fig3: Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.

   

  

  Fig4: Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.

   

  

  Fig5: Immunohistochemical analysis of paraffin-embedded human skin tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.

   

  

  Fig6: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.

   

  

  Fig7: Flow cytometric analysis of Daudi cells with HLA-DR antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).

特别提示：本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！